EBT-101 for HIV

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
HIVEBT-101 - Biological
Eligibility
18 - 65
Male
What conditions do you have?
Select

Study Summary

This trial will test a new drug, EBT-101, on people with HIV who are taking antiretroviral therapy.

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 48 weeks

48 weeks
Safety and Tolerability of EBT-101

Trial Safety

Trial Design

3 Treatment Groups

EBT-101 Dose-Level 2
1 of 3
EBT-101 Dose-Level 3
1 of 3
EBT-101 Dose-Level 1
1 of 3

Experimental Treatment

9 Total Participants · 3 Treatment Groups

Primary Treatment: EBT-101 · No Placebo Group · Phase 1

EBT-101 Dose-Level 2
Biological
Experimental Group · 1 Intervention: EBT-101 · Intervention Types: Biological
EBT-101 Dose-Level 3
Biological
Experimental Group · 1 Intervention: EBT-101 · Intervention Types: Biological
EBT-101 Dose-Level 1
Biological
Experimental Group · 1 Intervention: EBT-101 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 weeks

Who is running the clinical trial?

Excision BioTherapeuticsLead Sponsor
1 Previous Clinical Trials
9 Total Patients Enrolled
Study DirectorStudy DirectorExcision BioTherapeutics
1,070 Previous Clinical Trials
475,569 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · Male Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Cohort A will enroll male subjects only.
You are willing to enroll in the study and sign the informed consent.
Lab values are within the normal range.
You are willing and able to comply with all study-related procedures.
You have previously been vaccinated for N